Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib + anlotinib first-line therapy for EGFR-mutant NSCLC with brain metastases
ChiCTR2500106565Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib and anlotinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Henan Cancer Hospital. Primary endpoints: Safety (Phase I: safety lead-in) and Progression-Free Survival (PFS) (Phase II: formal study). Started Jul 2025; status: recruiting.
02
Drugs
furmonertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2500106565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106565.